Related Experiment Video
Updated: Aug 6, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
[Should the BCG vaccine still be recommended?]
G Collette1, M Bourhaba, M Moutschen
1Département de Médecine Générale, Université de Liège. gcollette@ulg.ac.be
Abstract:
The BCG vaccine has demonstrated its efficacy to protect young children from severe extrapulmonary forms of tuberculosis. Nevertheless, the immunity induced by the vaccine disappears in adults and cannot be boosted by readministration of BCG. Adverse effects of BCG are rare, but potentially dangerous (i.e. disseminated vaccinal infections) and they justify the fact that BCG should not be administered anymore in Western European countries where the incidence of pediatric tuberculous meningitis is very low. The vaccine is still recommanded for children living in countries with high tuberculosis prevalence and for resident children leaving Belgium for these countries.
More Related Videos
Related Concept Videos
Smallpox
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Vaccinations
Vaccines
Cross-reactivity
Immunological Memory
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature is...

